Nisa Leung
Nisa Leung is a Managing Partner of Qiming Venture Partners and leads its health care investments. Qiming Venture Partners is a leading investment firm in China that currently manages over USD 5.9 billion in assets and investment in over 380 companies. Nisa currently sits on the board of Gan & Lee Pharmaceuticals (SSE:603087), Zai Lab (NASDAQ:ZLAB; HKSE:9688), Venus MedTech (HKSE:2500), Nurotron, dMed, CanSino Biologics (SSE:688185; HKSE:6185), New Horizon Bio, Berry Oncology, Broncus, Insilico Medicine among others. She has been recognized by the Forbes Global 100 VC Midas List in 2019 and 2020 and named Top 3 Best Female Venture Capitalist in China by Forbes in 2018. Nisa earned her MBA from Stanford Graduate School of Business and a BS from Cornell University. She is currently visiting lecturer at Harvard Law School, member of Stanford Graduate School of Business Advisory Council, and board member of the Hong Kong Airport Authority and Hong Kong Palace Museum.
